MedTrace Logo

Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

NCT02204267 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3470

Last updated 2020-11-13

No results posted yet for this study

Summary

Investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atrial fibrillation.

Conditions

Interventions

OTHER

prolonged ECG monitoring

Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)

DEVICE

ECG

Sponsors & Collaborators

  • Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Matthias Endres, MD · Center for Stroke Research Berlin, Charité University Berlin, Campus Mitte

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-05-31
Completion
2020-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02204267 on ClinicalTrials.gov